Mantle Cell Lymphoma Excellence Forum

Mantle Cell Lymphoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Recent Breakthroughs in Therapies for Patients With Mantle Cell Lymphoma

10/23/2023

Featuring Tycel Phillips, MD

Tycel Phillips, MD, discusses 2 recent advancements in the treatment landscape of mantle cell lymphoma, including the use of BTK inhibitor pirtobrutinib, and CAR T-cell therapy treatment lisocabtagene maraleucel.

Tycel Phillips, MD, discusses 2...

10/23/2023

Oncology

Videos

Exploring the Efficacy of BTK Inhibitor Glofitamab Among Patients With R/R MCL

10/23/2023

Featuring Tycel Phillips, MD

Tycel Phillips, MD, reports updated findings from a phase 1/2 trial examining the efficacy and safety of glofitamab, a BTK inhibitor, among patients with heavily pretreated R/R mantle cell lymphoma.

Tycel Phillips, MD, reports...

10/23/2023

Oncology

Quiz

Venetoclax, Lenalidomide, and Rituximab Triplet Combination for MCL

10/18/2023

True or False: Findings from a single-arm study on the addition of venetoclax to lenalidomide and rituximab treatment for patients with previously untreated mantle cell lymphoma indicated that patients treated with this triplet combination...

True or False: Findings from a...

10/18/2023

Oncology

Quiz

Novel Therapeutic Target FGFR1 for Patients With MCL

10/10/2023

True or False: Findings from a study aiming to identify a regulator that directly contributes to the clinical outcomes of mantle cell lymphoma (MCL) indicated that fibroblast growth factor receptor-1 (FGFR1) overexpression in preclinical...

True or False: Findings from a...

10/10/2023

Oncology

Quiz

Significance of DTI for MCL Treatment Outcomes

09/25/2023

True or False: According to findings from a pooled analysis of 3 datasets assessing the potential significance of diagnosis to treatment interval (DTI) for the prognosis of mantle cell lymphoma, patients with shorter DTI were noted to have...

True or False: According to...

09/25/2023

Oncology

Videos

Addition of Venetoclax to Lenalidomide and Rituximab Therapy for Patients With Previously Untreated MCL

09/22/2023

Featuring Kami J. Maddocks, MD

Featuring Kami J. Maddocks, MD ...

Kami J. Maddocks, MD, discusses results from a single-arm study on the addition of venetoclax to a lenalidomide and rituximab regimen for patients with previously untreated mantle cell lymphoma.

Kami J. Maddocks, MD, discusses...

09/22/2023

Oncology

Videos

Exploring the Role of FGFR1 as a Therapeutic Target Among Patients With MCL

09/22/2023

Featuring Narendranath Epperla, MD, MS

Featuring Narendranath Epperla, MD, M...

Narendranath Epperla, MD, MS, discusses the current research on fibroblast growth factor receptor-1 as an up-and-coming and viable therapeutic target for patients with mantle cell lymphoma.

Narendranath Epperla, MD, MS,...

09/22/2023

Oncology

Quiz

Pirtobrutinib for High-Risk Subtypes of Mantle Cell Lymphoma

09/19/2023

True or False: Results of the BRUIN trial indicated that after receiving pirtobrutinib, patients with MCL with classical histology had more efficacious outcomes than patients with MCL with blastoid or pleomorphic variants.

True or False: Results of the...

09/19/2023

Oncology

Videos

Promising Advances in the Treatment of Patients With Mantle Cell Lymphoma

09/13/2023

Featuring Michael Wang, MD

At the 2023 Society of Hematologic Oncology Annual Meeting, Michael Wang, MD, reviews the latest research and treatment advances for patients with mantle cell lymphoma.

At the 2023 Society of...

09/13/2023

Oncology

Videos

Pirtobrutinib Demonstrates Durable Efficacy and Safety Among Patients With Covalent BTK Inhibitor Pretreated R/R MCL

09/05/2023

Featuring Kami J. Maddocks, MD

Featuring Kami J. Maddocks, MD ...

Kami J. Maddocks, MD, analyzes the updated results of the BRUIN trial on the efficacy and safety of pirtobrutinib among patients with high-risk heavily pretreated R/R mantle cell lymphoma with prior covalent BTK inhibitor therapy.

Kami J. Maddocks, MD, analyzes...

09/05/2023

Oncology

Recent News

Conference Insider

Dr Martin Discusses How to Approach MCL

03/23/2022

Emily Bader

Peter Martin, MD, discusses how to approach MCL, including what’s been learned so far and what’s to be expected, at the virtual Great Debates & Updates in Hematologic Malignancies.

Peter Martin, MD, discusses how...

03/23/2022

Oncology

News

Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors

05/17/2024

Stephanie Holland

Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...

Results from the ORANGE II PLUS...

05/17/2024

Oncology

News

FDA Grants Accelerated Approval to Tarlatamab for Patients With Extensive-Stage Small Cell Lung Cancer

05/17/2024

Stephanie Holland

Based on results from the DELLphi-301 trial, the FDA has granted accelerated approval to tarlatamab for patients with extensive-stage small cell lung cancer.

Based on results from the...

05/17/2024

Oncology

News

FDA Approves Lisocabtagene Maraleucel for Adult Patients With R/R Follicular Lymphoma

05/16/2024

Amber Denham

The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.

The US Food and Drug...

05/16/2024

Oncology

News

No Improvement From Adjuvant Radiotherapy Post-Prostatectomy for Patients With Prostate Cancer At Risk of Recurrence

05/14/2024

Stephanie Holland

According to long-term results from the RADICALS-RT study, adjuvant radiotherapy does not meaningfully improve disease control and increases the risk of urinary and bowel morbidities among patients with prostate cancer at risk of recurrence...

According to long-term results...

05/14/2024

Oncology

News

Datopotamab Deruxtecan Shows Promising Activity, Safety Among Heavily Pretreated Patients With HR-Positive, HER2-Negative, or Triple-Negative Breast Cancer

05/14/2024

Stephanie Holland

According to results from the ongoing phase 1 TROPION-PanTumor01 trial, datopotamab deruxtecan demonstrated promising efficacy and safety among heavily pretreated patients with advanced or metastatic HR-positive, HER2-negative, or...

According to results from the...

05/14/2024

Oncology

News

Addition of Vismodegib to Radiation Therapy Shows Promise Among Patients With Basal Cell Carcinoma

05/10/2024

Stephanie Holland

Results from a prospective, phase 2 study found the addition of induction and concurrent vismodegib to radiation therapy may be considered a therapeutic option for patients with locally advanced, unresectable basal cell carcinoma.

Results from a prospective,...

05/10/2024

Oncology

News

Frontline Rituximab-Bendamustine Followed by Rituximab Maintenance Demonstrates Improved PFS vs R-CHOP Therapy Among Patients With Follicular Lymphoma

05/08/2024

Amber Denham

According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...

According to a retrospective...

05/08/2024

Oncology

News

Post-Allogeneic Hematopoietic Cell Transplant Gilteritinib Maintenance Demonstrates Benefit for Patients With AML With Detectable FLT3-ITD MRD

05/03/2024

Amber Denham

According to a recent trial, patients with acute myeloid leukemia with FLT3-ITD and measurable residual disease detectable in the peri-transplant period derived benefit from post-transplant gilteritinib, whereas those without detectable MRD...

According to a recent trial,...

05/03/2024

Oncology

News

FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer

05/01/2024

Stephanie Holland

Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.

Based on results from the phase...

05/01/2024

Oncology

News

Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas

04/25/2024

Stephanie Holland

According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.

According to results from the...

04/25/2024

Oncology